Notice: This company has been marked as potentially delisted and may not be actively trading. Jounce Therapeutics (JNCE) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Taboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) PropertiesOctober 2, 2024 | markets.businessinsider.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusNovember 27, 2023 | bizjournals.comJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 19, 2023 | tmcnet.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 18, 2023 | finance.yahoo.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaSeptember 5, 2023 | tmcnet.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comTrading was temporarily halted for "JNCE" at 07:05 PM with a stated reason of "News pending."May 4, 2023 | marketbeat.comJounce Therapeutics Announces Closing of Tender OfferMay 3, 2023 | finance.yahoo.comJounce Therapeutics (NASDAQ:JNCE) Now Covered by StockNews.comStockNews.com initiated coverage on Jounce Therapeutics in a report on Sunday. They set a "hold" rating on the stock.April 30, 2023 | marketbeat.comJNCE Jounce Therapeutics, Inc.April 29, 2023 | seekingalpha.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableApril 17, 2023 | finance.yahoo.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 29, 2023 | benzinga.comBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | msn.comJounce Therapeutics Shares Rally on Buyout Deal >JNCEMarch 27, 2023 | marketwatch.comJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEMarch 27, 2023 | marketwatch.comJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsMarch 27, 2023 | finance.yahoo.comTrading was temporarily halted for "JNCE" at 08:03 AM with a stated reason of "News pending."March 27, 2023 | marketbeat.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 23, 2023 | benzinga.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 17, 2023 | 247wallst.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesMarch 16, 2023 | finance.yahoo.com10% Owner of Jounce Therapeutics Makes $85K BuyMarch 15, 2023 | benzinga.comWhy Jounce Therapeutics Stock Is Moving Higher Today?March 15, 2023 | finance.yahoo.comConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick FactsMarch 15, 2023 | markets.businessinsider.comTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)March 15, 2023 | msn.comJounce Therapeutics Jumps Premarket on Buyout Bid >JNCEMarch 15, 2023 | marketwatch.comWhy Is Jounce Therapeutics (JNCE) Stock Up 37% Today?March 15, 2023 | investorplace.comJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesMarch 15, 2023 | finance.yahoo.comJounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating accountMarch 13, 2023 | finance.yahoo.comJounce Therapeutics Full Year 2022 Earnings: Beats ExpectationsMarch 11, 2023 | finance.yahoo.comMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law FirmMarch 1, 2023 | benzinga.comJOUNCE THERAPEUTICS INVESTOR ALERT by the Former...March 1, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Jounce Therapeutics, Inc. MergerFebruary 23, 2023 | benzinga.comCambridge biotech Jounce to cut staff, merge with U.K. drug developerFebruary 23, 2023 | finance.yahoo.comJounce Therapeutics, Inc.: Redx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | finanznachrichten.deJounce Shares Bounce Higher on Tie-Up With Redx >JNCEFebruary 23, 2023 | marketwatch.comRaymond James downgrades Jounce Therapeutics (JNCE) to a HoldFebruary 23, 2023 | markets.businessinsider.comJounce stock soars ~35% on all-stock merger with Redx PharmaFebruary 23, 2023 | msn.comRedx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | finance.yahoo.comJounce Therapeutics Shares Up 12% After Hours On Layoff PlansFebruary 22, 2023 | marketwatch.comJounce Therapeutics Announces RestructuringFebruary 22, 2023 | finance.yahoo.comShort Interest in Jounce Therapeutics, Inc. (NASDAQ:JNCE) Declines By 46.3%Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 1,580,000 shares, a decrease of 46.3% from the December 31st total of 2,940,000 shares. Based on an average trading volume of 1,550,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 4.0% of the shares of the stock are sold short.January 27, 2023 | marketbeat.comCowen Financial Products LLC Ups Stake in Jounce Therapeutics Inc (JNCE)January 25, 2023 | nasdaq.comJounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Sold by Trv Gp II LLCTrv Gp II LLC decreased its stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) by 57.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 572,829 shares of the company's stock after selling 775,000 shares duringJanuary 20, 2023 | marketbeat.comAssenagon Asset Management S.A. Sells 571,100 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)Assenagon Asset Management S.A. lowered its stake in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) by 41.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 800,291 shares of the company's stock after sellJanuary 13, 2023 | marketbeat.comJNCE.O - | Stock Price & Latest News | ReutersJanuary 12, 2023 | reuters.comGilead's (GILD) Application for Trodelvy Gets EMA ValidationJanuary 4, 2023 | finance.yahoo.com Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available JNCE Media Mentions By Week JNCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JNCE News Sentiment▼0.000.59▲Average Medical News Sentiment JNCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JNCE Articles This Week▼00▲JNCE Articles Average Week Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRME News VYGR News JSPR News VALN News CCCC News FDMT News ITOS News ENGN News ATYR News ARTV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JNCE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jounce Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
